We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+27.98%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$300M
AUM Growth
+$102M
Cap. Flow
+$5.36M
Cap. Flow %
1.79%
Top 10 Hldgs %
74.87%
Holding
29
New
7
Increased
5
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$32.6M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$17.9M
3
DCOY
Decoy Therapeutics
DCOY
+$15.5M
4
ASMB icon
Assembly Biosciences
ASMB
+$6.36M
5
TVTX icon
Travere Therapeutics
TVTX
+$6.25M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$16.3M
2
MGNX icon
MacroGenics
MGNX
+$15.9M
3
KITE
Kite Pharma, Inc.
KITE
+$10.5M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$9.98M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
1
Atara Biotherapeutics
ATRA
$92.3M
$44.2M 14.73%
42,528
+27,123
+176% +$17.9M
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$29.7M 9.89%
+1,580,400
New +$32.6M
RCPT
3
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$24.9M 8.31%
151,301
+5,500
+4% +$696K
ASMB icon
4
Assembly Biosciences
ASMB
$694M
$20.8M 6.95%
131,176
+47,030
+56% +$6.36M
CLVS
5
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$18.6M 6.18%
+2,500
New +$177K
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$18M 6.01%
243,048
-141,300
-37% -$9.98M
KITE
7
DELISTED
Kite Pharma, Inc.
KITE
$16.2M 5.41%
281,400
-157,000
-36% -$10.5M
DCOY
8
Decoy Therapeutics
DCOY
$1.9M
$15.8M 5.26%
+1
New +$15.5M
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$682M
$14.4M 4.8%
1,074,600
– –
KYNB
10
Kyntra Bio
KYNB
$32.5M
$12.6M 4.18%
16,000
– –
TVTX icon
11
Travere Therapeutics
TVTX
$6.19B
$9.82M 3.27%
+410,000
New +$6.25M
KIN
12
DELISTED
Kindred Biosciences, Inc.
KIN
$9.24M 3.08%
1,294,431
– –
IRWD icon
13
CALL
Ironwood Pharmaceuticals
IRWD
$682M
$8M 2.67%
+5,970
New +$78.3K
GNVC
14
DELISTED
GenVec, Inc.
GNVC
$5.86M 1.95%
198,641
– –
SAGE
15
DELISTED
Sage Therapeutics
SAGE
$5.65M 1.88%
112,455
-378,589
-77% -$16.3M
ARRY
16
CALL
DELISTED
Array Biopharma Inc
ARRY
$5.42M 1.81%
7,350
-221,050
-97% -$1.57M
CALA
17
DELISTED
Calithera Biosciences, Inc
CALA
$4.85M 1.62%
14,774
+4,689
+46% +$1.67M
FWP
18
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$4.5M 1.5%
22,712
+8,426
+59% +$1.37M
XENE icon
19
Xenon Pharmaceuticals
XENE
$5.81B
$3.72M 1.24%
220,570
-107,500
-33% -$1.99M
FLXN
20
DELISTED
Flexion Therapeutics, Inc.
FLXN
$3.67M 1.22%
+162,900
New +$3.77M
GYRE icon
21
Gyre Therapeutics
GYRE
$699M
$1.84M 0.61%
787
– –
EPZM
22
CALL
DELISTED
Epizyme, Inc
EPZM
$282K 0.09%
+150
New +$3.1K
HALO icon
23
CALL
Halozyme
HALO
$12B
– –
-160,700
Closed -$1.55M
MGNX icon
24
MacroGenics
MGNX
$263M
– –
-453,626
Closed -$15.9M
PRTK
25
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-78,958
Closed -$3.04M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2015 Portfolio in Review

As of Q1 2015, EcoR1 Capital held 29 positions worth $300M, up 52% from $198M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital's Q1 2015 filing shows 7 new, 5 increased, 5 reduced and 6 closed positions. Its largest new stake was Epizyme, Inc: 1,580,400 shares worth $29.7M. The largest sale was Sage Therapeutics, an estimated $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q1 2015 buy was Epizyme, Inc: 1,580,400 shares worth $29.7M.
  • EcoR1 Capital added most to Atara Biotherapeutics in Q1 2015, an estimated $17.9M increase.
  • EcoR1 Capital's biggest Q1 2015 reduction was Sage Therapeutics, cutting an estimated $16.3M.
  • EcoR1 Capital fully exited MacroGenics in Q1 2015, selling an estimated $15.9M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $300M portfolio in Q1 2015.
  • EcoR1 Capital opened 7 new positions and closed 6 in Q1 2015.
  • EcoR1 Capital's portfolio value rose 52% quarter-over-quarter to $300M.

Based on EcoR1 Capital's 13F filing for Q1 2015, filed 15 May 2015.